What is Biogen's SKYCLARYS — total revenue?

Biogen (BIIB) reported SKYCLARYS — total revenue of $150.7M in Q1 2026.

How has Biogen's SKYCLARYS — total revenue changed year-over-year?

Biogen's SKYCLARYS — total revenue increased by 21.6% year-over-year, from $123.9M to $150.7M.

What does SKYCLARYS — total revenue mean?

This metric represents the total gross revenue generated from the sale of the pharmaceutical product SKYCLARYS, a treatment for Friedreich's ataxia. It reflects the commercial success and market adoption of this specific therapeutic asset within the company's rare disease portfolio. Tracking this revenue stream is essential for evaluating the growth trajectory of the company's specialized neurology pipeline.

Biogen BIIB SKYCLARYS — Total Revenue

Other product segments

TYSABRI

$441.5M+15.7%

SPINRAZA

$374M-11.8%

VUMERITY

$179M+29.0%

AVONEX

$163.2M-2.2%

BENEPALI

$122.1M+9.7%

TECFIDERA

$109.5M-46.9%

PLEGRIDY

$64.3M+8.1%

ZURZUVAE

$55.4M+100%

IMRALDI

$49.6M+4.6%

QALSODY

$32.5M+110%

FLIXABI

$10.5M-19.8%

BYOOVIZ

$0-100%

FAMPYRA

$0-100%

FUMADERM And ADUHELM

$0-100%

TOFIDENCE

$0-100%

Similar metrics at other companies

GILDYescarta — Total revenues

$332M-14.0%

ABBVSkyrizi — Net revenues

$4.48B+30.9%

SUPNAPOKYN — Total revenues

$7.73M-48.4%

AMGNKRYSTEXXA — Total revenues

$255M+8.1%

AMGNBLINCYTO — Total revenues

$415M+12.2%

BMYSprycel — Total Revenues

$73M-58.3%

Other financials

Income statement

See full

Revenue$2.5B+1.9%

Gross profit$1.8B+0.8%

Operating income$610.7M—

Net income$319.5M+32.8%

EPS (diluted)$2.15+31.1%

Balance sheet

See full

Cash & equivalents$3.4B+30.2%

Total debt$6.6B+34.7%

Total equity$18.7B+9.9%

Total assets$29.5B+5.2%

Cash flow

See full

Operating cash flow$645.5M+149%

CapEx$51.2M+38.0%

Free cash flow$594.3M+167%

Valuation

See full

Market cap$31.89B+72.3%

Enterprise value$35.07B+57.0%

P/E22.5×+10.4×

P/S3.2×+1.4×

Profitability

See full

Gross margin75.5%-0.1pp

Operating margin22.9%—

Net margin14.3%-0.8pp

FCF margin24.4%-0.4pp

Returns & leverage

See full

Return on equity8%-1.2pp

Debt / equity0.4×+0.1×

Current ratio3.1×+1.6×

Where this comes from

Reported directly by Biogen in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Biogen’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biogen's skyclarys — total revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Biogen's SKYCLARYS — total revenue?: Biogen (BIIB) reported SKYCLARYS — total revenue of $150.7M in Q1 2026.
How has Biogen's SKYCLARYS — total revenue changed year-over-year?: Biogen's SKYCLARYS — total revenue increased by 21.6% year-over-year, from $123.9M to $150.7M.
What does SKYCLARYS — total revenue mean?: This metric represents the total gross revenue generated from the sale of the pharmaceutical product SKYCLARYS, a treatment for Friedreich's ataxia. It reflects the commercial success and market adoption of this specific therapeutic asset within the company's rare disease portfolio. Tracking this revenue stream is essential for evaluating the growth trajectory of the company's specialized neurology pipeline.